Erlotinib monotherapy in patients with advanced non-small cell lung cancer: an effective approach with low toxicity
A Ardavanis, S Koumna, I Fragos, S Malliou… - Anticancer …, 2008 - ar.iiarjournals.org
Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase
inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib …
inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib …
[HTML][HTML] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 …
SM Lee, I Khan, S Upadhyay, C Lewanski… - The lancet …, 2012 - thelancet.com
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …
active supportive care because of poor performance status or presence of several …
Efficacy vs. effectiveness: erlotinib in previously treated non-small-cell lung cancer
N Sheikh, CR Chambers - Journal of Oncology Pharmacy …, 2013 - journals.sagepub.com
Background: A randomized trial carried out by Shepherd et al. in patients with advanced or
metastatic non-small-cell lung cancer showed statistically significant benefit of erlotinib over …
metastatic non-small-cell lung cancer showed statistically significant benefit of erlotinib over …
[HTML][HTML] Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study
K Kubota, Y Nishiwaki, T Tamura, K Nakagawa… - Journal of Thoracic …, 2008 - Elsevier
Introduction The aim of this study was to evaluate the efficacy and safety of Erlotinib in
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …
Safety of erlotinib in TRUST, a phase IV trial in patients with advanced non-small cell lung cancer (NSCLC): initial results from the East/South East (E/SE) Asian …
Y Wu, L Zhang, J Siu-Kie Au, A Cheng… - Journal of Clinical …, 2007 - ascopubs.org
18018 Background: Erlotinib significantly improved survival versus placebo and was well
tolerated in patients (pts) with previously treated advanced NSCLC in the phase III BR. 21 …
tolerated in patients (pts) with previously treated advanced NSCLC in the phase III BR. 21 …
[HTML][HTML] A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous …
T Ciuleanu, CM Tsai, CJ Tsao, J Milanowski… - Lung Cancer, 2013 - Elsevier
Background Molecularly targeted agents for non-small cell lung cancer (NSCLC) can
provide similar efficacy to chemotherapy without chemotherapy-associated toxicities …
provide similar efficacy to chemotherapy without chemotherapy-associated toxicities …
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy
M Tiseo, C Gridelli, S Cascinu, L Crinò, FV Piantedosi… - Lung Cancer, 2009 - Elsevier
BACKGROUND: Erlotinib demonstrated significantly prolonged survival versus placebo in
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …
Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study
Y Huang, L Zhang, Y Shi, S Ma, M Liao… - Japanese journal of …, 2015 - academic.oup.com
Objective This study is to analyze the data of Chinese subpopulation in the Tarceva Lung
Cancer Survival Treatment Study (TRUST-China) which was a global Phase IV study …
Cancer Survival Treatment Study (TRUST-China) which was a global Phase IV study …
Efficacy and clinical/molecular predictors of erlotinib monotherapy for Chinese advanced non-small cell lung cancer
Y Zhu, Y Xia, G Ren, M Wang, X Zeng… - Chinese medical …, 2010 - mednexus.org
Background A retrospective analysis of clinical data were conducted reviewing patients who
were given erlotinib at Peking Union Medical College (PUMC) Hospital from May 2005 to …
were given erlotinib at Peking Union Medical College (PUMC) Hospital from May 2005 to …